An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes
dc.contributor.author | Bou‐maroun, Laura M. | |
dc.contributor.author | Meta, Fabien | |
dc.contributor.author | Hanba, Curtis J. | |
dc.contributor.author | Campbell, Andrew D. | |
dc.contributor.author | Yanik, Gregory A. | |
dc.date.accessioned | 2017-12-15T16:48:41Z | |
dc.date.available | 2019-03-01T21:00:17Z | en |
dc.date.issued | 2018-01 | |
dc.identifier.citation | Bou‐maroun, Laura M. ; Meta, Fabien; Hanba, Curtis J.; Campbell, Andrew D.; Yanik, Gregory A. (2018). "An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes." Pediatric Blood & Cancer 65(1): n/a-n/a. | |
dc.identifier.issn | 1545-5009 | |
dc.identifier.issn | 1545-5017 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/140014 | |
dc.description.abstract | ObjectiveTo identify characteristics of pediatric sickle cell disease (SCD) hospitalizations and to examine admission demographics and medical expenditures.MethodsAdmissions with SCD were identified from the 2009 and 2012 releases of the Healthcare and Cost Utilization Project’s Kids Inpatient Database. Diseaseâ specific secondary diagnoses including acute chest syndrome (ACS), vasoâ occlusive pain crisis (VOC), splenic sequestration, and stroke/transient ischemic attack were analyzed for patient and hospital demographics. Analytical endpoints included total healthcare expenditures and mortality.ResultsWe reviewed 75,234 inpatient hospitalizations with a diagnosis of SCD. Over $900,000,000 was spent annually in associated healthcare expenditure. The median length of hospitalization stay (LOS) for all admissions was 3 days (interquartile range [IQR] 2â 5 days). VOC was the most frequent secondary diagnosis, recording 48,698 total hospitalizations and a median LOS of 3 days (IQR 2â 6 days). Of the 8,490 hospitalizations with ACS, the infant population had a significantly higher mortality rate compared to other age groups (2% vs. 0.3%, P < 0.001). Cerebral vascular accidents incurred the second highest median hospitalization cost ($18,956), behind ACS ($22,631). A high proportion of Caucasian patients died during hospitalization for VOC (0.4% vs. 0.1%, P = 0.014) and ACS (4% vs. 0.2%, P < 0.001) when compared to nonâ Caucasians.ConclusionInpatient hospitalizations for secondary manifestations of pediatric SCD were associated with significant healthcare expenditures. Patients with an increased statistical risk for death during hospitalization included Caucasians with SCD complications of ACS and VOC, and patients <1â yearâ old with ACS. Further research is needed to substantiate the associated clinical significance of these findings. | |
dc.publisher | McGrawâ Hill | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | splenic sequestration | |
dc.subject.other | vasoâ occlusive crisis | |
dc.subject.other | acute chest syndrome | |
dc.subject.other | cerebrovascular accident | |
dc.subject.other | hospitalization costs | |
dc.subject.other | kids inpatient database | |
dc.subject.other | sickle cell disease | |
dc.title | An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Pediatrics | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/140014/1/pbc26758.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/140014/2/pbc26758_am.pdf | |
dc.identifier.doi | 10.1002/pbc.26758 | |
dc.identifier.source | Pediatric Blood & Cancer | |
dc.identifier.citedreference | Topley JM, Rogers DW, Stevens MC, Serjeant GR. Acute splenic sequestration and hypersplenism in the first five years in homozygous sickle cell disease. Arch Dis Child. 1981; 56 ( 10 ): 765 â 769. | |
dc.identifier.citedreference | Ellison AM, Bauchner H. Socioeconomic status and length of hospital stay in children with vasoâ occlusive crises of sickle cell disease. J Natl Med Assoc. 2007; 99 ( 3 ): 192 â 196. | |
dc.identifier.citedreference | Panepinto JA, Brousseau DC, Hillery CA, Scott JP. Variation in hospitalizations and hospital length of stay in children with vasoâ occlusive crises in sickle cell disease. Pediatr Blood Cancer. 2005; 44 ( 2 ): 182 â 186. | |
dc.identifier.citedreference | Modell B, Darlison M, Birgens H, et al. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007; 67 ( 1 ): 39 â 69. | |
dc.identifier.citedreference | Roberts I, de Montalembert M. Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe. Haematologica. 2007; 92 ( 7 ): 865 â 871. | |
dc.identifier.citedreference | Wang Y, Kennedy J, Caggana M, et al. Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity. Genet Med. 2013; 15 ( 3 ): 222 â 228. | |
dc.identifier.citedreference | AHRQ. HCUP databases: KID overview. 2016. https://www.hcup-us.ahrq.gov/kidoverview.jsp. | |
dc.identifier.citedreference | Bekelis K, Connolly ID, Do HM, Choudhri O. Operative volume and outcomes of cerebrovascular neurosurgery in children. J Neurosurg Pediatr. 2016; 18 ( 5 ): 623 â 628. | |
dc.identifier.citedreference | Hanba C, Bobian M, Svider PF, et al. Perioperative considerations and complications in pediatric parathyroidectomy. Int J Pediatr Otorhinolaryngol. 2016; 91: 94 â 99. | |
dc.identifier.citedreference | Hanba C, Svider PF, Shkoukani MA, et al. Pediatric pituitary resection: characterizing surgical approaches and complications. Int Forum Allergy Rhinol. 2017; 7: 72 â 79. | |
dc.identifier.citedreference | Benson JM, Therrell BL, Jr. History and current status of newborn screening for hemoglobinopathies. Semin Perinatol. 2010; 34 ( 2 ): 134 â 144. | |
dc.identifier.citedreference | DeBaun MR, Strunk RC. The intersection between asthma and acute chest syndrome in children with sickleâ cell anaemia. Lancet. 2016; 387 ( 10037 ): 2545 â 2553. | |
dc.identifier.citedreference | Shapiro BS, Benjamin LJ, Payne R, Heidrich G. Sickle cellâ related pain: perceptions of medical practitioners. J Pain Symptom Manage. 1997; 14 ( 3 ): 168 â 174. | |
dc.identifier.citedreference | Haywood C, Jr., Tanabe P, Naik R, Beach MC, Lanzkron S. The impact of race and disease on sickle cell patient wait times in the emergency department. Am J Emerg Med. 2013; 31 ( 4 ): 651 â 656. | |
dc.identifier.citedreference | Brousse V, Elie C, Benkerrou M, et al. Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients. Br J Haematol. 2012; 156 ( 5 ): 643 â 648. | |
dc.identifier.citedreference | Brown AK, Sleeper LA, Miller ST, Pegelow CH, Gill FM, Waclawiw MA. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Arch Pediatr Adolesc Med. 1994; 148 ( 8 ): 796 â 804. | |
dc.identifier.citedreference | Owusuâ Ofori S, Remmington T. Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database Syst Rev. 2015 ( 9 ): CD003425. | |
dc.identifier.citedreference | Cherry MG, Greenhalgh J, Osipenko L, et al. The clinical effectiveness and costâ effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. Health Technol Assess. 2012; 16 ( 43 ): 1 â 129. | |
dc.identifier.citedreference | Cunninghamâ Myrie C, Abdulkadri A, Waugh A, et al. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: a cost effectiveness analysis. Pediatr Blood Cancer. 2015; 62 ( 10 ): 1862 â 1864. | |
dc.identifier.citedreference | Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemiaâ TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, openâ label, phase 3, nonâ inferiority trial. Lancet. 2016; 387 ( 10019 ): 661 â 670. | |
dc.identifier.citedreference | Oheneâ Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998; 91 ( 1 ): 288 â 294. | |
dc.identifier.citedreference | Schatz J. Brief report: academic attainment in children with sickle cell disease. J Pediatr Psychol. 2004; 29 ( 8 ): 627 â 633. | |
dc.identifier.citedreference | Smeltzer MP, Nolan VG, Yu X, et al. Distance from an urban sickle cell center and its effects on routine healthcare management and rates of hospitalization. Hemoglobin. 2016; 40 ( 1 ): 10 â 15. | |
dc.identifier.citedreference | Kressin NR, Chang BH, Hendricks A, Kazis LE. Agreement between administrative data and patients’ selfâ reports of race/ethnicity. Am J Public Health. 2003; 93 ( 10 ): 1734 â 1739. | |
dc.identifier.citedreference | Zingmond DS, Parikh P, Louie R, et al. Improving hospital reporting of patient race and ethnicityâ approaches to data auditing. Health Serv Res. 2015; 50 ( Suppl 1 ): 1372 â 1389. | |
dc.identifier.citedreference | Wolfson JA, Schrager SM, Coates TD, Kipke MD. Sickleâ cell disease in California: a populationâ based description of emergency department utilization. Pediatr Blood Cancer. 2011; 56 ( 3 ): 413 â 419. | |
dc.identifier.citedreference | Bunn HF, Aster J. Pathophysiology of blood disorders. New York: McGrawâ Hill; 2011. | |
dc.identifier.citedreference | CDC. Sickle cell disease data & statistics. 2016. http://www.cdc.gov/ncbddd/sicklecell/data.html. | |
dc.identifier.citedreference | Hoppe CC. Newborn screening for hemoglobin disorders. Hemoglobin. 2011; 35 ( 5â 6 ): 556 â 564. | |
dc.identifier.citedreference | Gavini N, Hoots WK, Mensah GA, Hanspal M. An analysis of the NIHâ supported sickle cell disease research portfolio. Blood Cells Mol Dis. 2015; 54 ( 2 ): 198 â 205. | |
dc.identifier.citedreference | Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010; 303 ( 13 ): 1288 â 1294. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.